New Application Deadlines:
February 12, 2008, June 12, 2008, October 12, 2008
Resubmission Deadlines:
March 12, 2008, July 12, 2008, November 12, 2008
The Pulmonary Hypertension Association (PHA) and the National Heart, Lung, and Blood Institute (NHLBI) wish to announce a program that will provide supplemental funding to an individual who receives an NHLBI Mentored Clinical Scientist Development Award (K08) or a Mentored Patient-Oriented Research Career Development Award (K23) for research on pulmonary hypertension.
The purpose of the Mentored Clinical Scientist Development Award (K08) is to support the development of outstanding clinician research scientists in the area of pulmonary hypertension. This mechanism provides specialized study for clinically trained professionals who are committed to a career in research in pulmonary hypertension and have the potential to develop into independent investigators. The award supports a 3 to 5-year period of supervised research experience that integrates didactic studies with laboratory or clinically based research. The proposed research should have both intrinsic research importance and be a vehicle for learning the methodology, theories, and conceptualizations necessary for a well trained independent researcher.
The purpose of the Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for 3 to 5 years of supervised study and research for clinically trained professionals who have the potential to develop into productive, clinical investigators focusing on patient-oriented research in pulmonary hypertension. For the purposes of this award, patient-oriented research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator directly interacts with human subjects. This area of research includes: 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials; and 4) development of new technologies. Candidates must demonstrate they have received or will participate in courses such as: data management, epidemiology, study design, hypothesis development, drug development, etc., as well as the legal and ethical issues associated with research on human subjects.
A comparison of the K08 and K23 mechanisms appears on the final page of the Program Announcement.
Peter Oishi, M.D.
University of California San Francisco
“Vascular Dysfunction with Increased Pulmonary Blood Flow: A Role for PPAR Gamma”
July 1, 2007 – June 30, 2012
Paul B. Yu, M.D., Ph.D.
Massachusetts General Hospital
“The Role of the BMP Type II Receptor in Vascular Function”
July 1, 2006 – June 30, 2011
Roberta L Keller, MD
University of California San Francisco
“Chronic Sildenafil for Severe Diaphragmatic Hernia”
July 1, 2005 - June 30, 2010
Theresa R. Grover, MD
University of Colorado Health Sciences Center and The Children’s Hospital Perinatal Research Facility
“Role of Vascular Endothelial Growth Factor in Neonatal Pulmonary Hypertension”
July 1, 2004 - June 30, 2009
Reda Girgis, MD
Division of Pulmonary & Critical Care Medicine - The Johns Hopkins University School of Medicine
“Statins in Experimental Pulmonary Hypertension”
July 1, 2003 - June 30, 2008
Program
Announcement 
